Table 1 Patient information
From: Confounding Effects of Benign Lung Diseases on Non-Small Cell Lung Cancer Serum Biomarker Discovery
Number of patients | Age (mean) | Gender (F/M) | Staging | Details | ||
|---|---|---|---|---|---|---|
Discovery survey | Lung cancer | 67 | 65.3 | 23/44 | Stage I, 34 | 32 squamous |
Stage II, 10 | 25 adenocarcinoma | |||||
Stage III, 21 | 10 other NSCLC | |||||
Stage IV, 2 | ||||||
Benign controls | 29 | 60.5 | 11/18 | – | 8 benign tumors | |
6 end stage lung disease | ||||||
15 pleuropulmonary sepsis | ||||||
Disease-free controls | 44 | 65.0 | 14/30 | – | – | |
Validation survey | Lung cancer | 30 | 69.0 | 10/20 | Stage I, 20 | 16 squamous |
Stage II, 4 | 10 adenocarcinoma | |||||
Stage III, 4 | 4 other NSCLC | |||||
Stage IV, 2 | ||||||
Benign controls | 12 | 58.5 | 5/7 | – | 5 benign tumors | |
4 end-stage lung disease | ||||||
3 pleuropulmonary sepsis | ||||||
Disease-free controls | 15 | 58.0 | 9/6 | – | – | |